Research around β2-glycoprotein I: A major target for antiphospholipid antibodies

References

• Schultze HE, Heideke K, Haput H. Uber ein bisher ubekanntes niedermolekulars β2-Globulin des Humanserums. Naturwissenschaften 1961; 48: 719
   Google Scholar
• Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–1547
   PubMed Web of Science ®Google Scholar
• McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–4124
   PubMed Web of Science ®Google Scholar
• Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177–178
   PubMed Web of Science ®Google Scholar
• Ohkura N, Hagihara Y, Yoshimura T, Goto Y, Kato H. Plasmin can reduce the function of human β2 glycoprotein I by cleaving domain V into a nicked form. Blood 1998; 91: 4173–4179
   PubMed Web of Science ®Google Scholar
• Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma β2-glycoprotein I. Proc Natl Acad Sci USA 1984; 81: 3640–3644
   PubMed Web of Science ®Google Scholar
• Kato H, Enjyoji K. Amino acid sequence and location of the disulfide bonds in bovine β2-glycoprotein I: The presence of five Sushi domains. Biochemistry 1991; 30: 11687–11694
   PubMed Web of Science ®Google Scholar
• Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, Gros P. Adhesion mechanism of human β(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166–5174
   PubMed Web of Science ®Google Scholar
• Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R. Crystal structure of human beta2-glycoprotein I: Implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228–6239
   PubMed Web of Science ®Google Scholar
• Matsuura E, Inagaki J, Kasahara H, Yamamoto D, Atsumi T, Kobayashi K, Kaihara K, Zhao D, Ichikawa K, Tsutsumi A, Yasuda T, Triplett DA, Koike T. Proteolytic cleavage of β2-glycoprotein I: Reduction of antigenicity and the structural relationship. Int Immunol 2000; 12: 1183–1192
   PubMed Web of Science ®Google Scholar
• Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457–462
   PubMed Web of Science ®Google Scholar
• Tsutsumi A, Ichikawa K, Matsuura E, Sawada K, Koike T. Heterogeneous behavior of anti-β2-glycoprotein I antibodies on various commercially available enzyme immunoassay plates coated with β2-glycoprotein I. J Rheumatol 2000; 27: 391–396
   PubMed Web of Science ®Google Scholar
• Shi W, Chong B, Hogg P, Chesterman C. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 342–345
   PubMed Web of Science ®Google Scholar
• Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of Factor XII in plasma by β2-glycoprotein I and anti-β2-glycoprotein I. Thromb Haemost 1995; 73: 798–804
   PubMed Web of Science ®Google Scholar
• Nimpf J, Wurm H, Kostner GM. β2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 109–114
   PubMed Web of Science ®Google Scholar
• Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K, Koike T. Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999; 42: 167–174
   PubMedGoogle Scholar
• Forastiero RR, Martinuzzo ME, Lu L, Broze GJ. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost 2003; 1: 1764–1770
   PubMed Web of Science ®Google Scholar
• Nakaya Y, Schaefer EJ, Brewer HBJ. Activation of human post heparin lipoprotein lipase by apolipoprotein H (β2-glycoprotein I). Biochem Biophys Res Commun 1980; 95: 1168–1172
   PubMed Web of Science ®Google Scholar
• Wurm H, Beubler E, Polz E, Holasek A, Kostner G. Studies on the possible function of β2-glycoprotein-I: Influence in the triglyceride metabolism in the rat. Metabolism 1982; 31: 484–486
   PubMed Web of Science ®Google Scholar
• Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569–573
   PubMed Web of Science ®Google Scholar
• Chonn A, Semple SC, Cullis PR. β2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of “non-self” particles. J Biol Chem 1995; 270: 25845–25849
   PubMed Web of Science ®Google Scholar
• Manfredi AA, Rovere P, Galati G, et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998; 41: 205–214
   PubMed Web of Science ®Google Scholar
• Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of β2-glycoprotein I. Arthritis Rheum 1998; 41: 215–223
   PubMed Web of Science ®Google Scholar
• Takeuchi R, Atsumi T, Ieko M, Takeya H, Yasuda S, Ichikawa K, Tsutsumi A, Suzuki K, Koike T. Coagulation and fibrinolytic activities in 2 siblings with beta(2)-glycoprotein I deficiency. Blood 2000; 96: 1594–1595
   PubMed Web of Science ®Google Scholar
• Yasuda S, Tsutsumi A, Chiba H, Yanai H, Miyoshi Y, Takeuchi R, et al. β2-glycoprotein I deficiency: Prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000; 152: 337–346
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Kawamura M, Ichikawa K, Suzuki T, Sumida T, Yoshida S, Matsuura E, Ikehara S, Koike T. Anticardiolipin antibodies in NZW × BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992; 149: 1063–1068
   PubMed Web of Science ®Google Scholar
• Suzuki T, Takabayashi K, Ichikawa K, Itou I, Ishiguro N, Yoshiki T, Koike T. Effects of monoclonal anticardiolipin antibody on pregnant mice. J Rheumatol 1996; 23: 83–86
   PubMed Web of Science ®Google Scholar
• George J, Blank M, Gilburd B, Hojnik M, Shenkman B, Tamarin I, Varon D, Matsuura E, Koike T, Shoenfeld Y. Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human β2-glycoprotein I. Int Immunol 1997; 9: 913–921
   PubMed Web of Science ®Google Scholar
• Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 1997–2002
   PubMed Web of Science ®Google Scholar
• Mann K. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165–174
   PubMed Web of Science ®Google Scholar
• Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 1328–1332
   PubMed Web of Science ®Google Scholar
• Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997; 77: 222–223
   PubMed Web of Science ®Google Scholar
• Cuadrado MJ, Lopez-Pedreira C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 834–841
   PubMed Web of Science ®Google Scholar
• Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276–281
   PubMed Web of Science ®Google Scholar
• Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, Furusaki A, Bohgaki T, Amengual O, Amasaki Y, Koike T. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2glycoprotein I antibodies. Int Immunol 2004; 16: 1633–1641
   PubMed Web of Science ®Google Scholar
• Matsuura E, Igarashi J, Kasahara H, Yamamoto D, Atsumi T, Kobayashi K, et al. Proteolytic cleavage of β2-glycoprotein I: Reduction of antigenicity and the structural relationship. Intern Immunol 2000; 12: 1183–1192
   PubMed Web of Science ®Google Scholar
• Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. β2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999; 81: 87–95
   PubMed Web of Science ®Google Scholar
• Itoh Y, Inuzuka K, Kohno I, Wada H, Shiku H, Ohkura N, Kato H. Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: Measurement with a monoclonal antibody specific for a nicked form of domain V. J Biochem (Tokyo) 2000; 128: 1017–1024
   PubMed Web of Science ®Google Scholar
• Yasuda S, Atsumi T, Ieko M, Matsuura E, Kobayashi K, Inagaki J, Kato H, Tanaka H, Yamakado M, Akino M, Saitou H, Amasaki Y, Jodo S, Amengual O, Koike T. Nicked beta2-glycoprotein I: A marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004; 103: 3766–3772
   PubMed Web of Science ®Google Scholar
• Takeuchi R, Atsumi T, Ieko M, Amasaki Y, Ichikawa K, Koike T. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: Possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002; 119: 781–788
   PubMed Web of Science ®Google Scholar
• Ieko M, Ichikawa K, Atsumi T, Takeuchi R, Sawada KI, Yasukouchi T, Koike T. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin Thromb Hemost 2000; 26: 85–90
   PubMed Web of Science ®Google Scholar